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Abstract
Background: Surgery and Anesthesia cause an excessive pro-inflammatory response. Mulago Hospital is faced with staff  short-
age making post-operative pain management difficult.Interleukin-6 (IL-6) drives inflammatory pain, endothelial cell dysfunction 
and fibrogenesis. Ketamine is cheap and, readily available. We hypothesized that its attenuation of  serum IL-6 was a surrogate 
for clinical benefit.
Materials and methods: Institutional Review Board’s approval was sought and RCT was registered at clinical trials.gov (iden-
tifier number: NCT01339065).  Consenting patients were randomized to receive pre-incision intravenous ketamine - 0.5mg/kg 
or 0.9% saline placebo in weighted dosing. Blood samples were collected and laboratory analyzed at baseline, post-operatively in 
PACU, 24 and 48 hours respectively.
Results: We recruited 39 patients of  whom 18 were randomized to the ketamine arm and 21 in the placebo arm with follow up 
at 24 and 48 hours. Serum IL-6 and IL-1β levels were analyzed using ELIZA assay of  pre-coated micro wells.  Ketamine sup-
pressed serum IL-6 at PACU with reduced increase at 24 hours. There was no reaction in 98% of  IL-1β assayed.
Conclusion: Low-dose ketamine attenuated early serum IL-6 levels due to surgical response with reduced 24 hour increase, but 
the difference was not statistically significant and we recommend more studies.
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Anaesthesia and surgery cause immune system impair-
ment expressed as excessive pro-inflammatory respons-
es leading to exacerbated pain, poor wound healing, 
psychological stress coupled with complications such as 
sepsis or acute respiratory distress syndrome (ARDS)1-
4.  Post-operative pain management remains a challenge 
even in advanced health systems like the USA, where 50-
70% patients experience post-operative pain5. Enhanced 
surgical inflammation and pain is mediated by hormonal 
and cytokine cascade responses6,7.  Interleukin 6 (IL-6) 
affects the immune system homeostatic processes with 
context-dependent pro- and anti-inflammatory proper-
ties that have become a prominent target for clinical in-
tervention to improve disease outcome and patient well-
being by focusing on how and when to block it8.
Mulago National Referral and Teaching Hospital (MN-
RTH) is Uganda’s only tertiary hospital with a bed capac-
ity of  1500 beds and an accident and emergency depart-
ment that receives about 48,000 patients per year9.  There 
is poor staff  motivation, overcrowding, limited quality as-
surance and a cumbersome procurement system10.  This 
is compounded by a poorly funded health system due to 
meagre resources as Uganda is classified as a Low In-
come Country (LIC) and Heavily Indebted Poor Country 
(HIPC)11.
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Ketamine is an N-Methyl-D-Aspartate (NMDA) recep-
tor antagonist which in low sub-anaesthetic doses pro-
duces analgesia by desensitization of  sensitized Central 
Nervous System (CNS) NMDA receptors thus inhib-
iting pain transmission12-14. Ketamine is used as a ‘third 
line’ treatment for chronic pain relief  when convention-
al treatments have failed14.  It is the favoured induction 
anaesthetic for non-contraindicated and hypovolemic 
patients due to its catecholamine release effects and se-
dation15,16. It also attenuates post-operative delirium after 
major cardiac surgery17.
Surgical inflammation  is consistently associated with  IL-
6  whose serum levels increase by 1–3 hours, peaking at 
4-24 hours and remaining elevated for 48 –72 hours18. 
The greater the surgical trauma, the greater the serum 
IL-6 response e.g. abdominal surgery produces a bigger 
response than hip replacement19. Comparatively  IL-1β 
and TNF are detectable in much lower serum levels than 
IL-6 after elective surgery  although in both haemor-
rhagic and septic shock, results have shown significantly 
elevated levels of  IL-1β, TNF and IL-6 with increased 
risk of  ARDS, multiple organ failure and death20-22. Ket-
amine affects post-operative inflammation in cardiopul-
monary bypass by cytokine production attenuation23.  We 
thus hypothesized that pre-incision low dose intravenous 
ketamine would attenuate post-operative IL-6 and IL-1β 
production. This reduction would be a surrogate of  good 
post-operative clinical course as studies showed good 
post-operative pain reduction when using ketamine as an 
adjuvant in multi-modal management strategy24.
Materials and methods
This study was approved by the Makerere Universi-
ty’s School of  Medicine Research and Ethics Commit-
tee (SOMREC) and was registered at clinicaltrials.gov 
(Identifier: NCT01339065). We conducted a prospective, 
randomized, double-blind, placebo-controlled trial from 
January to March 2011 among patients due for elective 
abdominal or perineal surgery in MNRTH.
We enrolled consenting patients with inclusion criteria 
of  American society of  anaesthesiologist (ASA) class 1 
and 2, adult Patients (18-70 years) scheduled for elective 
abdominal or perineal surgery. We excluded hyperten-
sives or those having blood pressures above 140/100 for 
3 consistent readings 15 minutes apart, septic or febrile 
patients(T >38°C), pheochromocytoma patients, neu-
ro-surgery patients, epileptics, emergencies’ or spinal and 
local infiltration anaesthesia plus those that received in-
tra-operative blood transfusion.
Sample size calculation was done using Stuart JP’s formu-
la basing on power of  90% with standard deviation of  
75 of  post-operative IL-6 level at 4 hours after surgery 
in the cardiopulmonary bypass study23.  This gave us a 
total patient estimate (N) of  thirty (30) with fifteen (15) 
in each arm.
Randomization and concealment: Participants were 
randomly assigned according to body weight to receive 
either ketamine 0.5mg/kg or placebo using blocks of  4. 
A statistician independent of  the study generated sequen-
tial random treatment codes using a computer program. 
To enable blinding, a pharmacist at a separate location 
pre-mixed the two interventions in similar brand and 
consistency sterile 10 mls syringes and these syringes had 
10 mg/ml colourless solution that catered for a lowest 
possible weight of  20 kg and highest possible weight of  
200 kg.
Concealment was achieved by labelling each syringe accord-
ing to the sequential random treatment codes and placed 
in an opaque carrier bag that was brought to the main 
operating room (OR) on the morning of  surgery.
Procedure: patients were taken through the consent process 
during the pre-operative visits and at the OR a syringe was 
blindly picked from the opaque carrier bag in presence of  
a theatre nurse with its code becoming the patient’s study 
number. The patients’ baseline weight, blood pressure 
and temperature were recorded as per flow chart.
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In theatre a 5 mls baseline blood sample was collected 
under asepsis from an accessible vein and was stored at 
room temperature to allow some clotting before lab cen-
trifuge for analysis.  General anaesthesia was induced by 
slow thiopentone (2mg/kg) bolus, followed by opiate an-
algesia of  intravenous morphine (0.1 mg/kg) and suxa-
methonium 100 mg for intubation then Isoflurane-oxy-
gen mixture was used for anaesthesia maintenance.  At 
pre-incision, we administered the clear colourless syringe 
contents to patients according to randomization.  Fluid 
and volume replacement and monitoring were done as 
per MNRTH OR protocols. Surgery duration was noted 
and patients were extubated awake at the end of  surgery.
Post-operatively, patients were monitored in the post 
-anaesthesia care unit (PACU) where a second 5 mls of  
blood was collected before transfer back to ward. Patients 
were followed up at 24 and 48 hours for third and fourth 
sample collection respectively with clinical patient assess-
ment. Tramadol was our post-operative pain analgesic for 
the study duration after which they reverted back to MN-
RTH standard of  care i.e. intramuscular diclofenac of  or 
pethidine.  The collected samples were centrifuged then 
stored at sub-zero temperatures for standard ELISA anal-
ysis at Makerere University’s licenced and internationally 
certified immunology laboratory as per procured ELIZA 
kits (Biolegend- San Diego, CA, USA). This was done 
under strict protocols as per international Quality As-
surance (QA) standards under the laboratory manager’s 
supervision.  The incubated samples were read by ELI-
ZA readers using optical densities, first for blanks then 
standard dilutions of  pre-packed for IL-1beta or IL-6 
ELIZA antibody reagents from Bio legend- San Diego, 
CA, USA. The blanks and standard optical densities  were 
used as the Y-axis with corresponding concentrations in 
the X-axis and a standard curve was calculated using a 
computer generated 4-PL curve-fit to get a best fit curve 
through these points and the interleukin concentrations 
were read off  according to their corresponding Optical 
density from ELIZA reader (See Bar graph1) .
 
Data collection and management: Interviewer-administered 
and pre-tested questionnaires were used for data collec-
tion. The data was cleaned, coded, and double-entered 
into Epidata version 3.1 using Epi-Info 6.04® and an-
alysed using SPSS version 16 (SPSS Inc., Chicago, IL, 
USA). The participants’ characteristics were summarized 
using means, medians and standard deviations that were 
presented using tables and histograms. Categorical vari-
Received 0.5 mg/kg ketamine before incision
Determined IL 6 and then IL 1β levels 
using ELISA and then extent of effect 
by statistical analysis of the levels
Patients due for surgery on the days operating list were assessed for eligibility
Followed up at PACU, 24 and 48 hours post 
operatively also get blood samples for IL 1β & IL 6
Received Placebo before incision
Followed up at PACU, 24 and 48 hours post 
operatively also get blood samples for IL 1β 
and IL 6
Randomized allocation on the morning of surgery at theatre holding area, patient’s baseline temperature; 
BP& weight were obtained
Excluded patients with raised BP>14/90 
15minutes apart and Temperature>38°C
Determined IL 6 and then IL 1β levels using 
ELISA and then extent of effect by statistical 
analysis of the levels
Detailed study information was given and consent was obtained and any other clarification given
Under asepsis Baseline blood sample were taken off followed by randomization to receive either intervention 
then standard GA of Thiopentone, Suxamethonium and maintained on Isoflurane-Oxygen inhalation anaesthetic. 
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ables were summarized using proportions, percentages 
and presented using pie charts or bar charts.
Our primary specific objective was to determine change 
in levels of  IL- 6 inflammatory marker after surgery from 
baseline, immediately after surgery in PACU, at 24 hours 
and 48 hours.  Our secondary objective was to assess the 
IL- 1β levels at similar time points.
Data was analysed using ANOVA or the Kruskal–Wallis 
tests as appropriate for association between changes of  
levels of  IL-6 and IL-1β with each predictor, proportions 
compared using chi-square and odds ratios.  Data was 
assessed for normal distribution of  variance using nor-
mality plots and the Kolmogorov–Smirnov test. Categor-
ical data was analysed using Fisher’s exact test and naive 
pooled analysis was performed for each subject providing 
one data point for the fit. A p-value of  ≤ 0.05 was consid-
ered statistically significant
Results
We enrolled 39 patients that were randomized to receive 
0.5mg/kg of  ketamine (18) or 0.9% normal saline pla-
cebo (21) respectively. The baseline characteristics were 
similar in both groups i.e. age, sex, ASA score and type of  
surgery. The majority of  patients were aged 18-28 years 
(Table 1). 
Mean weight was 60 kgs with mean surgery duration of  
1 hour (shortest procedure being 20 minutes for exam-
ination under anaesthesia and longest being 4.5 hours for 
ureteroplasty). Statistically no relevant change was no-
ticed in clinical variables of  our study participants as vital 
signs did not deviate from normal values during and after 
surgery (table 2 and table 3). Gender had no statistically 
significant bearing on the outcome (p= 0.522).
 Table 1: Age characteristics of enrolled patients 
Age 
group   (years)      
 Ketamine n[%] Placebo n[%] 
18-28 4 (25) 10 (43.5%) 
29-38 5 (31.3) 3 (13%) 
39-48 2 (12.5) 4 (17.4) 
49-58 3 (18.8) 2 (8.7) 
58-70 2 (12.5) 4 (17.4) 
  
Table 2: Baseline characteristics for study participants 
Age in years 
 
n (%) Percent 
 
18 - 28 14(35.9) 35.9 
 
29 - 39 9 (23.08) 23.08 
 

















Time taken for 


















99.41 ± 0.94 
  





Clinical Parameter Before (n +/- SD) After(n+/- SD) 
 MAP (mmHg) 90 +/- 9 90 +/- 8 
Systolic BP 130 +/- 11 126 +/- 11 
Diastolic BP 75 +/- 13 71 +/- 13 
HR 84 +/-15 95 +/- 15 
SPO2 100 +/- 1 100 +/- 1 
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Table 4: Changes in IL-6 levels in both groups from base line to 48 hours 
COLLECTION TIME KETAMINE GROUP 
Median IL-6 pg/ml (n± SD) 
PLACEBO GROUP 
Median IL-6 pg/ml (n± SD) 
p-value 
Baseline 10 ±167 15 ±261 0.508 
PACU 6.5  ± 232 20 ± 171 0.412 
24 hours 50 ± 285 90 ± 167 0.402 
48 hours 50 ± 316 48 ±54  0.373 
 
Figure 1:    Median serum IL- 6 levels for primary outcome 
 
 
On sample analysis in the laboratory, we noted that IL- 6 
levels in the ketamine group dropped from baseline in the 
PACU while those in the placebo group started increas-
ing.  At 24 hours Eliza analysis showed a median IL-6 
level increase in both groups with a much higher increase 
in the placebo group (90+/- 167 picogrammes/ml) than 
in the ketamine group (50 +/-285 picogrammes/ml).   At 
48 hours IL-6 median concentrations showed a drop in 
the placebo group while the ketamine group remained 
stable (table 4 and figure 1).
Figure 2: Showing median changes from baseline readings for IL-6 
 
Figure 2: Showing median changes from baseline readings for IL-6 
 
Generally, when compared to the ketamine group the pla-
cebo group showed IL-6 increase from baseline peaking 
at 24 hours as illustrated in figure 2.  However the above 
findings had P-value of  ≥0.05 which was statistically in-
significant.   There were no detectable ELIZA readings 
in 98% IL1-β pre-coated antibodies micro wells analysed. 
We had no mortality at the end of  the study.
Side effects: There was one case of  excess salivation af-
ter induction which had 0.4mg of  atropine administered 
and suctioning done. We also had a PACU case of  awak-
ening hallucination managed with diazepam 1mg.  
Table 4: Changes in IL-6 levels in both groups from base line to 48 hours 
COLLECTION TIME KETAMINE GROUP 
Median IL-6 pg/ml (n± SD) 
PLACEBO GROUP 
Median IL-6 pg/ml (n± SD) 
p-value 
Baseline 10 ±167 15 ±261 0.508 
PACU 6.5  ± 232 20 ± 171 0.412 
24 hours 50 ± 285 90 ± 167 0.402 
48 hours 50 ± 316 48 ±54  0.373 
 
Figure 1:    Median serum IL- 6 levels for primary outcome 
 
 
African Health Sciences Vol 17 Issue 2, June, 2017 504
Discussion
This study was done to determine and compare the effect 
of  pre-incision 0.5mg/kg ketamine on the post-operative 
serum IL-6 and IL-1 β cytokine levels. We found that ket-
amine group had an early marked reduction of  IL-6 se-
rum levels in the PACU with reduced elevation at 24 and 
48 hours when compared to the placebo group, a finding 
similar to cardiac bypass surgery studies that showed IL-6 
serum level reduction over a 7 day post-operative peri-
od23.  We focused on IL-6, its serum concentration is a 
good indicator of  inflammatory cascade activation and 
a predictor of  subsequent morbidity and mortality21,24,25. 
Also cytokine attenuation reduces acute neutrophil infil-
tration which causes surgical inflammation followed by 
tissue damage from accumulation of  neutrophil-secreted 
proteases and reactive oxygen-species26.
Ketamine was chosen because it is inexpensive, readily 
available in MNRTH and it has multiple beneficial prop-
erties with regard to modulating inflammation as shown 
by systematic reviews27. Its other clinical benefits such as 
its bronchodilator effects are used in ICU to improve se-
vere bronchospasm, asthma exacerbation or status asth-
maticus28, and its anti-inflammatory effects render it the 
drug of  choice for use in septic surgical patients29-30.   
Surgical tissue damage causes glutamate release sensitiz-
ing the central pain pathway by activation of  post-syn-
aptic NMDA receptors in the spinal cord, manifesting 
clinically as heightened pain sensation31 and ketamine’s 
NMDA blockade hence reduces post-operative pain sen-
sation.
The IL-6 serum level reduction would reduce patients 
morbidity i.e. pain and infections as it is involved in the 
acute phase response to injury and infection32. This ex-
plains our study’s increased IL-6 levels for both the in-
tervention and control group after 24-48 hours.  Our 
postulated improvement of  post-operative clinical course 
was also strengthened because the NMDA receptor that 
ketamine antagonises has a role in CNS processing of  
pain12,31.   Cytokine attenuation is also clinically beneficial 
in the paediatric setting for Neisseria meningitis manage-
ment with erythropoietin33.
Limitations
Our study limitations include: (a) a small sample size that 
gave statistically insignificant but remarkable IL-6 serum 
level reduction, (b) inability to follow up other clinical 
outcomes past the 48 hours study time.  
Conclusion and recommendations   
Low-dose ketamine attenuated early IL-6 response to sur-
gery with reduced increase at 24 and 48 hours, but the 
difference did not reach statistical significance probably 
because of  small sample size and wide variations in IL-6 
values.
We recommend further and larger sample sized studies to 
explore ketamine’s post-operative benefits as pain man-
agement remains a challenge in Uganda with inadequate 
supply of  analgesics among anesthetic providers with 
only 45% having either pethidine or morphine available 
and 21% never having them available34. In MNRTH this 
is further compounded by overwhelming patient num-
bers and glaring staff  shortages of  a nurse: patient ratio 
of  1:40 at a given time35. 
 
Competing interests 
This was an academic thesis research for Dr. TS Luggya’s 
Masters of  Medicine in Anaesthesia and Critical Care36 
and the authors declare that they have no competing in-
terests.
Co- author contribution:              
• JMK and TR supervised, guided and reviewed the re-
search.
• LS and A Kintu assisted with patient recruitment, data 
management, lab follow up and final manuscript proof  
reading.
• JVBT and A Kwizera helped with conceptualization, 
proposal development and literature search guidance.
Author’s information/details:
a) TSL: Lecturers in the  Department of  Anaesthesia and 
is head of  the Mulago Trauma Unit
b) TR: Is an Anesthesiologist at Seattle hospital and Hon-
orary lecturer at Makerere University
c) SL: is a Cardiac and Critical Care Anaesthesiologist at 
the Uganda Heart Institute
d) JMK:  is an Anaesthesiologist and deputy clinical head 
Mulago Hospital
e) AK and AK are lecturers in the Department of  Anaes-
thesia  Makerere University
f) JVBT: is a retired lecturer in the Department of  An-
aesthesia
Acknowledgement  
A vote of  thanks goes to the members and colleagues 
African Health Sciences Vol 17 Issue 2, June, 2017505
in the Department of  Anaesthesia, Makerere University 
and dedicated staff  in Mulago hospital. Also to our de-
partments partners; Association of  Anaesthesiologists of  
Great Britain and Ireland (AAGBI) and Global Partners 
in Anaesthesia and Surgery (GPAS).
  
References
1. Brand JM, Kirchner H, Poppe C, Schmucker P. Cy-
tokine release and changes in mononuclear cells in pe-
ripheral blood under the influence of  general anesthesia. 
Anaesthesist. 1998 May;47(5):379-86. German. PubMed 
PMID: 9645277.
2. Borgermann J, Friedrich I, Flohe S, Spillner J, Majet-
schak M, Kuss O, et al. Tumor necrosis factor-alpha pro-
duction in whole blood after cardiopulmonary bypass: 
downregulation caused by circulating cytokine-inhibitory 
activities. J Thorac Cardiovasc Surg. 2002 Sep; 124(3):608-
17.
3. Antonelli M, Testa G, Tritapepe L, D'Errico RR, Costa 
D, Giovannelli L, et al. IL-8, IL-6 and ICAM-1 in serum 
of  paediatric patients undergoing cardiopulmonary by-
pass with and without cardiocirculatory arrest. J Cardiovasc 
Surg (Torino).1999 Dec; 40(6):803-9.
4. Bartoc C, Frumento RJ, Jalbout M, Bennett-Guerre-
ro E, Du E, Nishanian E: A randomized, double-blind, 
placebo-controlled study assessing the anti-inflammatory 
effects of  ketamine in cardiac surgical patients. J Cardio-
thorac Vasc Anesth. 2006 Apr;20(2):217-22.
5. Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postopera-
tive pain experience: Results from anational survey sug-
gest postoperative pain continues to be undermanaged. 
Anesth Analg 2003; 97:534-40.
6. Chambrier C, Chassard D, Bienvenu J, Saudin F, Paturel 
B, Garrigue C, et al. Cytokine and hormonal changes after 
cholecystectomy. Effect of  ibuprofen pre-treatment. Ann 
Surg. 1996 Aug; 224(2):178-82.
7. Clark JD, Shi X, Li X, Qiao Y, Liang D, Angst MS, et al. 
Morphine reduces local cytokine expression and neutro-
phil infiltration after incision. Mol Pain. 2007;3:28.
8. Christopher A Hunter, Simon A Jones. IL-6 as a key-
stone cytokine in health and disease. Nature Immunology 
16, 448–457 (2015) doi:10.1038/ni.3153.
9. Africa Business pages. Health and beauty category: 
Mulago hospital. http://directory.africa-business.com/
business/496bd3238f/Mulago-Hospital.
10.  Kizza IB, Tugumisirize J, Tweheyo R, Mbabali S, 
Kasangaki A, Nshimye E et al. Makerere University Col-
lege of  Health Sciences' role in addressing challenges 
in health service provision at Mulago National Referral 
Hospital. BMC Int Health Hum Rights. 2011 Mar 9;11 Sup-
pl 1:S7.
11.  Heavily Indebted Poor Countries: https://en.wikipe-
dia.org/wiki/Heavily_indebted_poor_countries.
12.  Paoletti P, Neyton J. NMDA receptor subunits: func-
tion and pharmacology. Curr Opin Pharmacol 2007; 1:39–
47. Epub 2006 Nov 7.
13.  Niesters M, Dahan A, Swartjes M, Noppers I, Fill-
ingim RB, Aarts L, et al: Effect of  ketamine on endoge-
nous pain modulation in healthy volunteers. Pain. 2011 
Mar;152(3):656-63.doi:10.1016/j.pain.2010.12.015. Epub 
2011 Jan 14. PubMed PMID: 21237568.
14.  G Hocking and MJ Cousins; “Ketamine in chronic 
pain management: an evidence-based review,” Anesthesia 
& Analgesia, vol. 97, no. 6, pp. 1730–1739, 2003 PubMed .
15.  Chernow B, Laker CR, Creuss D, Coyle J, Hughes P, 
Balestrieri F, et al. Plasma, urine, and cerebrospinal fluid 
catecholamine concentration during and after ketamine 
sedation. Crit Care Med. 1982;10:600–3.
16.  Jesse b Hall, Gregory Schmidt, Lawrence wood Prin-
cipals of  critical care, 3’rd edition pg# 203, 604.
17.  Hudetz JA, Patterson KM, Iqbal Z, Gandhi SD, Byrne 
AJ, Hudetz AG, et al. Ketamine attenuates delirium after 
cardiac surgery with cardiopulmonarybypass. J Cardio-
thorac Vasc Anesth. 2009 Oct; 23(5):651-7. doi:10.1053/j.
jvca.2008.12.021. Epub 2009 Feb 23. PubMed PMID: 
19231245.
18.  Roumen RM, Hendriks T, van der Ven-Jongekrijg J, 
Nieuwenhuijzen GA, Sauerwein RW, van der Meer JW, 
et al. Cytokine patterns in patients after major vascular 
surgery, hemorrhagic shock, and severe blunt trauma. 
Relation with subsequent adult respiratory distress syn-
drome and multiple organ failure. Ann Surg. 1993 Dec; 
218(6):769-76. PubMed PMID: 8257227; PubMed Cen-
tral PMCID: PMC1243073.
19.  Biffl WL, Moore EE, Moore FA, Peterson VM. Inter-
leukin-6 in the injured patient. Marker of  injury or media-
tor of  inflammation? Ann Surg 1996; 224: 647-64.
20. Martin C, Boisson C, Haccoun M, Thomachot L, 
Mege JL. Patterns of  cytokine evolution (tumor necrosis 
factor-alpha and interleukin-6) after septic shock, hemor-
rhagic shock, and severe trauma. Crit Care Med 1997; 25: 
1813-9 PubMed .
21. Casey LC, Balk RA, Bone RC. Plasma cytokine and 
endotoxin levels correlate with survival in patients with 
the sepsis syndrome. Ann Intern Med 1993; 119: 771-8 
PubMed. 
African Health Sciences Vol 17 Issue 2, June, 2017 506
22.  Kalff  JC, Turler A, Schwarz NT, Schraut WH, Lee 
KK, Tweardy DJ, et al. Intra-abdominal activation of  a lo-
cal inflammatory response within the human muscularis 
externa during laparotomy. Ann Surg 2003; 237: 301-15.
23.  Roytblat L, Talmor D, Rachinsky M, Greemberg L, 
Pekar A, Appelbaum A, et al. Ketamine attenuates the 
interleukin-6 response after cardiopulmonary bypass. 
Anesth Analg. 1998 Aug; 87(2):266-71. PubMed PMID: 
9706914.
24.  Shalaby MR, Waage A, Aarden L, Espevik T. En-
dotoxin, tumor necrosis factor-alpha and interleukin-1 
induce interleukin-6 production in vivo. Clin ImmunolIm-
munopathol 1989;53:488-98.
25.  Cruickshank AM, Fraser WD, Burns HJ, Van Damme 
J, Shenkin A.  Response of  serum interleukin-6 in patients 
undergoing elective surgery of  varying severity. Clin Sci 
(Lond). 1990 Aug;79(2):161-5. PubMed PMID: 2167805.
26. Jürgen Scheller, Athena Chalaris, Dirk Schmidt-Ar-
ras,Stefan Rose-John: The pro- and anti-inflammatory 
properties of  the cytokine interleukin-6. Biochimica et 
Biophysica Acta (BBA) - Molecular Cell Research, Vol-
ume 1813, Issue 5, May 2011, Pages 878–888. http://dx.
doi.org/10.1016/j.bbamcr.2011.01.034.
27.  Dale O, Somogyi AA, Li Y, Sullivan T and Shavit 
Y: Does intra-operative ketamine attenuate inflammatory 
reactivity following surgery? A systematic review and me-
ta-analysis. Anesth Analg. 115:934–943. 2012.
28.  Shweta Goyal, Amit Agrawal. Ketamine in status 
asthmaticus: A review. Indian J Crit Care Med. 2013 May-
Jun; 17(3): 154–161. doi:  10.4103/0972-5229.117048.
29.  Ward JL, Harting MT, Cox CS Jr and Mercer DW: 
Effects of  ketamine on endotoxin and traumatic brain 
injury induced cytokine production in the rat. J Trauma. 
70:1471–1479. 2011.
30.  Takahashi T, Kinoshita M, Shono S, Habu Y, Ogu-
ra T, Seki S, et al: The effect of  ketamine anesthesia on 
the immune function of  mice with postoperative septice-
mia. Anesth Analg. 2010 Oct;111(4):1051-8. doi: 10.1213/
ANE.0b013e3181ed12fc. Epub 2010 Aug 12. PubMed 
PMID: 20705789.
31.  B A Orser, P S Pennefather, and J F MacDonald, 
“Multiple mechanisms of  ketamine blockade of  N-meth-
yl-D-aspartate receptors,” Anesthesiology, vol. 86, no. 4, pp. 
903–917, 1997.
32. P C Heinrich, J V Castell, and T Andus: Interleu-
kin-6 and the acute phase response. Biochem J. 1990 Feb 1; 
265(3): 621–636
33. C Schultz, J Zimmer, C Härtel, J Rupp, P Temming, 
and T Strunk.. Attenuation of  monocyte proinflam-
matory cytokine responses to Neisseria meningitidis in 
children by erythropoietin. Clin Exp Immunol. Nov 2008; 
154(2): 187–191. doi:  10.1111/j.1365-2249.2008.03760.x
34. Hodges SC, Mijumbi C, Okello M, McCormick 
BA,Walker IA, Wilson IH. Anaesthesia services in devel-
oping countries: defining the problems. Anaesthesia 2007; 
62: 4–11
35. Ozgediz D, Galukande M, Mabweijano J, Kijjam-
bu S, Mijumbi C, Dubowitz G et al. The neglect of  the 
global surgical workforce: experience and evidence from 
Uganda. World J Surg. 2008;32(6):1208–15. doi:10.1007/
s00268-008-9473-4. PubMed PMID:18299920
36. The effect of  ketamine on production of  inflammato-
ry markers in post-operative patients in Mulago hospital: 
a randomized clinical trial. Dr Luggya Tonny’s thesis at 
the Department Anaesthesia, College of  Health Sciences 
of  Makerere University.
African Health Sciences Vol 17 Issue 2, June, 2017507
